Search results
Showing 31 to 45 of 149 results for nice conference
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .
Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)
Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .